Royalty Pharma Plc Stock Current Valuation
| RPRX Stock | USD 26.43 0.03 0.11% |
Valuation analysis of Royalty Pharma Plc helps investors to measure Royalty Pharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to drop to 9.18 in 2024. Enterprise Value Multiple is likely to drop to 9.18 in 2024. Fundamental drivers impacting Royalty Pharma's valuation include:
Price Book 1.7093 | Enterprise Value 17.6 B | Enterprise Value Ebitda 9.1543 | Price Sales 6.8721 | Forward PE 8.547 |
Undervalued
Today
Please note that Royalty Pharma's price fluctuation is very steady at this time. Calculation of the real value of Royalty Pharma Plc is based on 3 months time horizon. Increasing Royalty Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Royalty Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Royalty Stock. However, Royalty Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 26.43 | Real 32.08 | Target 48.67 | Hype 26.28 | Naive 26.8 |
The intrinsic value of Royalty Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Royalty Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Royalty Pharma Plc helps investors to forecast how Royalty stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Royalty Pharma more accurately as focusing exclusively on Royalty Pharma's fundamentals will not take into account other important factors: Royalty Pharma Plc Company Current Valuation Analysis
Royalty Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Royalty Pharma Current Valuation | 17.59 B |
Most of Royalty Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Royalty Pharma Plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Royalty Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Royalty Pharma is extremely important. It helps to project a fair market value of Royalty Stock properly, considering its historical fundamentals such as Current Valuation. Since Royalty Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Royalty Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Royalty Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Royalty Current Valuation Historical Pattern
Today, most investors in Royalty Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Royalty Pharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Royalty Pharma current valuation as a starting point in their analysis.
Royalty Pharma Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Royalty Pharma Plc has a Current Valuation of 17.59 B. This is 22.44% higher than that of the Pharmaceuticals sector and 278.57% higher than that of the Health Care industry. The current valuation for all United States stocks is 5.78% lower than that of the firm.
Royalty Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Royalty Pharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Royalty Pharma could also be used in its relative valuation, which is a method of valuing Royalty Pharma by comparing valuation metrics of similar companies.Royalty Pharma is currently under evaluation in current valuation category among its peers.
Royalty Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Royalty Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Royalty Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Royalty Fundamentals
| Return On Equity | 0.17 | ||||
| Return On Asset | 0.0569 | ||||
| Profit Margin | 0.51 % | ||||
| Operating Margin | 1.30 % | ||||
| Current Valuation | 17.59 B | ||||
| Shares Outstanding | 444.3 M | ||||
| Shares Owned By Insiders | 13.16 % | ||||
| Shares Owned By Institutions | 72.76 % | ||||
| Number Of Shares Shorted | 14.55 M | ||||
| Price To Earning | 37.70 X | ||||
| Price To Book | 1.71 X | ||||
| Price To Sales | 6.87 X | ||||
| Revenue | 2.35 B | ||||
| Gross Profit | 1.33 B | ||||
| EBITDA | 1.89 B | ||||
| Net Income | 1.13 B | ||||
| Cash And Equivalents | 1.47 B | ||||
| Cash Per Share | 3.34 X | ||||
| Total Debt | 6.14 B | ||||
| Debt To Equity | 0.68 % | ||||
| Current Ratio | 2.07 X | ||||
| Book Value Per Share | 15.40 X | ||||
| Cash Flow From Operations | 2.99 B | ||||
| Short Ratio | 8.05 X | ||||
| Earnings Per Share | 2.54 X | ||||
| Price To Earnings To Growth | 5.51 X | ||||
| Target Price | 41.53 | ||||
| Beta | 0.47 | ||||
| Market Capitalization | 15.57 B | ||||
| Total Asset | 16.38 B | ||||
| Retained Earnings | 2.52 B | ||||
| Working Capital | 1.11 B | ||||
| Current Asset | 10.66 M | ||||
| Current Liabilities | 2.31 M | ||||
| Annual Yield | 0.03 % | ||||
| Net Asset | 16.38 B | ||||
| Last Dividend Paid | 0.83 |
About Royalty Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Royalty Pharma Plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Royalty Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Royalty Pharma Plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Royalty Stock Analysis
When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.